Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl Fumarate in MCI and Alzheimer's Disease
NCT06850597Phase 2Recruiting
- Sponsor
- Medical University of Lodz
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dimethyl fumarate in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by Medical University of Lodz. Primary endpoint: Repeatable Battery for the Assessment of Neuropsychological Status at 15 months. Started Oct 2024; status: recruiting.
02
Drugs
dimethyl fumarate
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06850597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850597.